Irritable Bowel Syndrome Treatment Market size Worth US$ 2,300 Million by 2023 With North America Positioned as the Primary Growth Engine – Coherent Market Insights
The global irritable bowel syndrome treatment market was pegged at US$ 726.1 million in 2016, and is projected to record a tremendous CAGR of 12.9% over the forecast period (2017-2025).
Growing prevalence of irritable bowel syndrome (IBS) associated with lifestyle factors, stress, and increasing number of options for the treatment are expected to be the major factors driving the growth of the global irritable bowel syndrome treatment market over the forecast period. The leading manufacturers around the globe are working on upgrading the available treatment options for irritable bowel syndrome, besides developing new solutions for the condition. For instance, Allergan Plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) that is intended for the treatment of IBS in 2015. Valeant Pharmaceuticals International, Inc. received the U.S. FDA approval for Xifaxan for the treatment of IBS-D in 2015.
To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/506
The key market players are expanding their product portfolios through the adoption of growth strategies, such as mergers and acquisitions. Moreover, these players working to spread awareness about IBS through direct-to-consumer campaign advertisements for IBS drugs. For instance, Allergan and Ironwood Pharmaceuticals jointly launched their first DTC campaign for Viberzi in 2015.
At present, manufactures are engaged in the development of new gastrointestinal therapies for IBS treatment, with major R&D investments for the pipeline products. For instance, in 2017, Synergy Pharmaceuticals, Inc. announced the acceptance of supplemental new drug application for Trulance (Plecanatide) intended for the IBS treatment. Furthermore, Sucampo Pharmaceuticals, Inc.’s pipeline products include lubiprostone for pediatric functional constipation in phase two and lubiprostone alternate formulation for pediatric constipation, Furthermore, Ardelyx, Inc. reported the successful phase 3 T3MPO trial of Tenapanor in IBS patients suffering from acute constipation. Astellas Pharma, Inc. is conducting clinical trials for ASP7147, in the treatment of IBS. Norgine B.V. is having Plenvu, as osmotic laxative in clinical trials and the company entered into an agreement with Noventure to commercialize Gelsectan in Spain, Portugal and Andorra in 2017.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/506
Key Takeaways:
- Owing to the presence of high potential markets, especially across regions, including Asia Pacific, Latin America, the Middle East, and Africa, the global irritable bowel syndrome treatment market is projected to witness rampant growth over the estimated period.
- Technological developments in drug therapies, coupled with increasing awareness about the IBS physiology, is substantially driving the growth of the global irritable bowel syndrome treatment market.
- The well-known players operating in the global irritable bowel syndrome treatment market include Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/irritable-bowel-syndrome-treatment-market-to-surpass-us-2300-million-threshold-by-2025-globally-with-north-america-positioned-as-the-growth-engine-240
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Drug Type
- Market Snippet By Medical Condition
- Market Snippet By Distribution Channel
- Market Snippet By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Consumer Trends
- Impact Analysis
- FDA Approval Timeline
- PEST Analysis
- Probiotics & Prebiotics
- Market Dynamics
- Global Irritable Bowel Syndrome Treatment Market, By Drug Type, 2017 – 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Lubiprostone
- Linaclotide
- Eluxadoline
- Rifaximin
- Ramosetron Hydrochloride
- Others
- Introduction
- Global Irritable Bowel Syndrome Treatment Market, By Medical Condition, 2017 – 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- IBS – Constipation
- IBS – Diarrhea
- Introduction
- Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacie
- Introduction
- Global Irritable Bowel Syndrome Treatment Market, By Regions, 2017 – 2025 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- U.K.
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- China
- Japan
- ASEAN
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- Mexico
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- South Africa
- Rest of Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Medical Condition, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2025 (US$ Mn)
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Synergy Pharmaceuticals, Inc.
- Sucampo Pharmaceuticals, Inc.
- Valeant Pharmaceuticals International, Inc.
- Ardelyx, Inc.
- Astellas Pharma Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Ironwood Pharmaceuticals, Inc.
- Abbott Laboratories
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
